Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Elong Power Holding Limited (ELPW) is up 57% at $5.65 - Citizens, Inc. (CIA) is up 17% at $5.78 - The Oncology Institute, Inc. (TOI) is up 17% at $3.08 - Everbright Digital Holding Limited (EDHL) is up 12% at $3.89 - Universal Electronics Inc. (UEIC) is up 10% at $4.06 - Korro Bio, Inc. (KRRO) is up 9% at $12.57 - Silvaco Group, Inc. (SVCO) is up 9% at $3.60 - Clene Inc. (CLNN) is up 7% at $6.38 - AleAnna, Inc. (ANNA) is up 7% at $3.91 - Klarna Group plc (KLAR) is up 5% at $15.40 [3] Premarket Losers - KinderCare Learning Companies, Inc. (KLC) is down 32% at $2.30 - PAR Technology Corporation (PAR) is down 23% at $12.22 - EverCommerce Inc. (EVCM) is down 23% at $9.25 - SenesTech, Inc. (SNES) is down 21% at $1.78 - Once Upon A Farm, PBC (OFRM) is down 18% at $16.60 - PagerDuty, Inc. (PD) is down 12% at $6.35 - SciSparc Ltd. (SPRC) is down 10% at $4.25 - Agape ATP Corporation (ATPC) is down 9% at $5.09 - OIO Group (OIO) is down 9% at $3.28 - Lifetime Brands, Inc. (LCUT) is down 6% at $3.24 [4]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from the transition to managing Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% in 2025 from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million in 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88% in 2025, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on scaling current initiatives and maintaining resource allocation discipline while searching for a new CEO [5] - The company aims to accelerate growth in e-commerce, municipal adoption, and technology validation while managing operating expenses carefully [11] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for growth in 2026, aiming for higher revenue growth rates than in 2025 [13] - The company is focused on maintaining financial discipline while investing in areas with traction, such as e-commerce and municipal markets [11] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company ended 2025 with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - Revenue will come from a mix of e-commerce, municipal orders, and international expansion [14][15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company does not expect recurring legal costs related to this issue [22][23] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring regarding product registration [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based and aligned with long-term shareholder value [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: Will the company expand its sales team? - Yes, the company plans to expand its sales team to maximize B2B sales efforts [60]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from the transition to managing Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on scaling current initiatives and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, particularly in e-commerce and municipal markets [13][15] - The company is focused on maximizing growth while ensuring profitability [13] - Management is confident in the potential for improvement in financial performance and is preparing for increased demand [45][46] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [72] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management aims for higher growth rates, particularly in areas where they can maximize profitability [13] Question: What will contribute to 2026 revenues? - Revenue will come from a mix of e-commerce, municipal orders, and international expansion [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation will be equity-based and aligned with long-term shareholder value [56] Question: How is the agricultural sector performing? - The agricultural sector is expanding, with successes noted in almond groves and poultry [33] Question: Will the company expand its sales team? - Yes, the company plans to expand its sales team to maximize B2B sales efforts [60]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 20% to approximately $2.2 million, compared to $1.86 million in 2024. Excluding a temporary revenue impact from transitioning to direct management of Amazon sales, full-year revenue growth would have been closer to 30% [6][10] - Gross margin improved to 62.5% from 54.1% in 2024, reflecting an improved product mix and a growing contribution from e-commerce channels [10] - The company reported a net loss of $6.4 million for 2025, compared to a net loss of $6.2 million in 2024. Adjusted net loss for the year would have been approximately $5.6 million when excluding one-time legal expenses [10][11] - Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024 [11] - The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway [11] Business Line Data and Key Metrics Changes - E-commerce revenue increased by 88%, driven by strong growth on Amazon and the direct-to-consumer website, now representing more than half of total revenue [7][8] - Municipal markets are seeing increased interest in fertility control approaches, with ongoing programs in cities like New York and Chicago [8][9] Market Data and Key Metrics Changes - Internationally, the company expanded its footprint with regulatory approvals in New Zealand and new distribution relationships in Belize [9] - The company is in discussions with potential deployment partners in New York City as the trial of Evolve concludes [9] Company Strategy and Development Direction - The company's core strategy remains focused on delivering current initiatives, scaling areas with traction, and maintaining resource allocation discipline [5] - The board is engaged in finding a new CEO to help scale the business and build on progress made [4][5] - The company aims to maintain financial discipline while investing in areas with traction, including e-commerce expansion and municipal adoption [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating growth in 2026, aiming for higher growth rates than 2025 [13] - The company is focused on a mixture of revenue contributors, including e-commerce, municipal orders, and international expansion [15][17] - Management is confident in the potential for improvement in profitability and revenue growth [45] Other Important Information - The legal dispute with Liphatech has been resolved satisfactorily, with all litigation dismissed [10][22] - The company is preparing for a significant year ahead, with expectations for growth in various markets [74] Q&A Session Summary Question: Should we expect similar growth rates in 2026 as in 2025? - Management indicated that growth could be higher, aiming to accelerate growth in profitable areas [13] Question: What will contribute to 2026 revenues? - A mixture of e-commerce, municipal orders, and international expansion is expected to drive revenue [15] Question: What is the status of the court case with Liphatech? - The case has been settled satisfactorily, and the company considers it a past issue [22] Question: What is the status of product registration in Australia? - Regulatory authorities are expected to provide a response in the spring [25] Question: Will the new CEO have incentives based on stock performance? - Yes, a meaningful portion of the CEO's compensation is expected to be equity-based [56] Question: How is the agricultural sector performing? - The agricultural sector is performing well, with expansions in various areas including almond groves and poultry [33] Question: What municipalities besides New York City are evaluating Evolve? - Baltimore and Chicago are mentioned, with ongoing assessments in various neighborhoods [32] Question: Will the sales team be expanded? - Yes, the company plans to expand the sales team to maximize B2B sales efforts [61]

Product Development and Innovation - Evolve Rat, launched in January 2024, is the primary revenue-generating product, utilizing cottonseed oil to reduce fertility in rats[25]. - Evolve Mouse was introduced in May 2024, targeting mouse populations with similar technology as Evolve Rat, and is authorized for sale in 37 states[27]. - ContraPest is registered in all 50 states and is the first EPA-registered liquid contraceptive bait for rodent control, aligning with the EPA's push for non-lethal alternatives[41]. - Evolve Rat is exempt from federal registration due to its classification as a minimum risk pesticide, allowing for broader marketability[26]. - The company is focusing on ongoing product innovation and regulatory approvals for ContraPest and Evolve, both in the U.S. and globally[51]. - The company has filed a U.S. utility patent application for Evolve, which, if issued, would provide protection through 2044[76]. - Evolve meets EPA requirements as a minimum risk product, exempting it from federal registration[67]. Market and Sales Performance - The company is exploring international markets for Evolve products through distributors[28]. - Evolve is authorized for sale in 48 states and territories, while ContraPest is registered in all 50 states and the District of Columbia[84]. - The company has demonstrated over 90% reduction in rat populations through its fertility control products when integrated into an Integrated Pest Management (IPM) strategy[61]. - Revenues for the year ended December 31, 2025, were $2.2 million, a 20% increase from $1.9 million in 2024, driven primarily by the Evolve product line, which accounted for 81% of total revenue[183]. - Gross profit for 2025 was $1.4 million, resulting in a gross profit margin of 62.5%, up from $1.0 million and a 54.1% margin in 2024, attributed to the favorable mix of Evolve products[185]. - Evolve products, launched in January 2024, significantly contributed to revenue growth, with sales increasing across all major distribution channels, including e-commerce and retail[178]. Financial Performance and Challenges - The company reported net losses of $6.4 million and $6.2 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $142.5 million as of December 31, 2025[138]. - The company has incurred significant operating losses every quarter since inception and anticipates continuing to incur substantial losses in the future[138]. - The company expects to incur substantial and increased expenses as it continues to develop and market its proprietary products and product candidates[139]. - The company may face unforeseen expenses and complications that could adversely affect its financial condition and ability to achieve market acceptance for its products[140]. - The company's recurring losses from operations and negative cash flows raised substantial doubt about its ability to continue as a going concern, which was alleviated by successful equity raises during the year[219]. Operational Risks and Regulatory Environment - Regulatory changes by the EPA may shift market preferences towards non-lethal solutions, impacting traditional rodenticide use[45]. - Regulatory approval processes for product candidates are lengthy and unpredictable, and failure to obtain such approvals could jeopardize the company's business[97]. - The company is currently facing economic uncertainty, which may adversely affect customer spending and revenue due to inflation and geopolitical instability[95]. - The potential for increased tax liabilities due to changing regulations could adversely affect the company's results of operations[96]. - The company may need to seek strategic partners for manufacturing and distribution earlier than desired, potentially on less favorable terms[93]. Human Resources and Management - The company has 23 full-time employees, with 11 engaged in manufacturing, quality assurance, and R&D[74]. - The company currently has 23 full-time employees and one part-time employee, indicating a need for additional personnel to support future growth[113]. - The board of directors oversees the company's cybersecurity risk management framework, ensuring alignment with overall business objectives[163]. Cybersecurity and Legal Risks - The company is subject to various cybersecurity risks that could negatively impact its reputation and business operations[136]. - The company has implemented various cybersecurity measures to manage risks to its information systems and data[159]. - The company faces risks related to legal proceedings that could result in significant harm to its financial condition and operating results[128]. Financing and Capital Structure - The company plans to finance its cash needs primarily through the sale of equity securities and debt financings, with no committed external funding currently available[143]. - Future financing efforts may present challenges, potentially affecting stockholder rights and causing stock price declines due to dilution[144]. - Cash and cash equivalents at the end of 2025 were $7.6 million, a significant increase from $1.3 million at the end of 2024, bolstered by $13.2 million in net proceeds from equity transactions[191]. - The company has never declared or paid cash dividends on its common stock and intends to retain all available funds for operations and growth[173]. Inventory and Asset Management - Inventory is valued at the lower of cost or net realizable value, with quarterly evaluations to determine any necessary write-downs for obsolete or excess inventory[204]. - The company had property and equipment purchases of $84,000 in 2024, offset by proceeds of $28,000 from the sale of certain equipment[201]. - In 2025, cash used in investing activities included purchases of held-to-maturity investments of $3.0 million and property and equipment purchases of $138,000, with maturities of held-to-maturity investments at $2.0 million[201].

Financial Performance - Revenue increased by 20% to $2.2 million in 2025 compared to 2024, with an estimated 30% growth excluding the impact of transitioning to direct Amazon management[5] - Gross profit margin improved to 62.5% in 2025 from 54.1% in 2024, driven by higher margins from the Evolve product line[5] - Net loss for 2025 was $6.4 million, slightly higher than the $6.2 million loss in 2024; adjusted net loss would have been $5.6 million excluding one-time legal expenses[5] - Adjusted EBITDA loss improved to $5.3 million in 2025 from $5.8 million in 2024, reflecting revenue growth and improved gross margins[5] - E-commerce revenue surged 88% year-over-year, with a potential growth of 130% if the transition-related revenue loss of $200,000 had been recognized[5] Strategic Initiatives - Direct management of Amazon sales is expected to enhance revenue and margins once fully integrated, despite a $200,000 revenue impact during the transition[5] - SenesTech's Board initiated a search for a new CEO following the retirement of Joel Fruendt, appointing Dr. Jamie Bechtel as Interim Executive Chair[6] Operational Highlights - Field validation showed a 79% decline in rat activity at one site and over 50% at another within five months of deploying Evolve products[5] - The company ended 2025 with cash and short-term investments of $8.6 million, sufficient to support operations through approximately Q2 2027[5] Balance Sheet Strength - The total assets increased to $12.8 million in 2025 from $3.3 million in 2024, reflecting a strengthened balance sheet[16]

Core Insights - SenesTech reported a 20% increase in revenue to $2.2 million for 2025, driven by strong growth in e-commerce channels despite a transition to direct management of Amazon sales [1][2] - The company improved its gross profit margin to 62.5% in 2025 from 54.1% in 2024, attributed to the higher margin profile of the Evolve product line and manufacturing improvements [1] - Adjusted EBITDA loss decreased to $5.3 million in 2025 from $5.8 million in 2024, reflecting revenue growth and improved gross margins [1] Financial Highlights - Cash and short-term investments reached $8.6 million at the end of 2025, providing an operating runway through approximately the second quarter of 2027 [1] - Net loss for 2025 was $6.4 million, slightly higher than the $6.2 million loss in 2024, which included one-time legal expenses of $631,000 and non-cash operating lease expenses of $135,000 [1] - E-commerce revenue surged by 88% year-over-year, with a potential growth of 130% if the transition-related revenue loss of $200,000 had been recognized [1] Operational and Strategic Highlights - The company initiated a search for a new CEO following the retirement of Joel Fruendt and appointed Dr. Jamie Bechtel as Interim Executive Chair [1] - Evolve secured regulatory approval in New Zealand and expanded its international presence in Belize [1] - Field validation studies showed a 79% reduction in rat activity at one site and over 50% at another, demonstrating the effectiveness of the Evolve product [1] E-commerce Strategy - SenesTech transitioned to directly managing Amazon sales of Evolve products, which is expected to enhance revenue and operating margins once fully integrated [1] - The transition to direct management resulted in an estimated $200,000 revenue impact in the fourth quarter, but management anticipates higher revenue and stronger margins in the future [1]

Core Viewpoint - SenesTech, Inc. will report its financial results for the fourth quarter and fiscal year 2025 on March 12, 2026, after market close, with a conference call scheduled for the same day at 5:00 p.m. Eastern time [1]. Financial Reporting - The financial results will cover the period ended December 31, 2025, and will be accessible via a live webcast on the company's Investor Relations website [1]. - A replay of the conference call will be available for at least 90 days following the event [1]. Company Overview - SenesTech is focused on managing rodent populations through innovative birth control solutions, aiming to create healthier environments [1]. - The company's flagship product, Evolve rodent birth control, is designed to enhance pest management programs while reducing reliance on traditional poisons [1]. - SenesTech's mission includes creating cleaner cities, more efficient businesses, and healthier communities through effective and sustainable products [1].

Core Insights - SenesTech reported significant reductions in rodent activity following the deployment of Evolve® Rat Birth Control in urban field studies, indicating the product's effectiveness in managing rodent populations [1] Group 1: Study Results - In Location A, rodent presence decreased by 88% and the proportion of tracking plates with rodent tracks fell from 74% to 15%, representing a 79% reduction over five months [1] - In Location B, track density declined by 71%, with plate presence reducing to 47% from an initial 98%, indicating over a 50% reduction in overall presence [1] - The study utilized standardized tracking plates to measure rodent activity, showing measurable reductions in both prevalence and intensity within five months of Evolve deployment [1] Group 2: Company Mission and Product Impact - SenesTech aims to create healthier environments by managing pest populations through birth control, enhancing pest management programs while reducing reliance on traditional poisons [1] - The company emphasizes that Evolve Rodent Birth Control is effective as it reduces reproduction rates in rats, leading to decreased populations [1] - The results from these studies are critical for municipalities and pest management professionals in evaluating the potential for broader deployment of fertility control solutions [1]

Core Insights - SenesTech, Inc. is transitioning to directly manage sales of its Evolve™ Rat and Evolve™ Mouse products on Amazon, reflecting a strategic focus on e-commerce as a key distribution channel [1] - The company anticipates that this change will increase revenue and enhance margins in the e-commerce segment, building on previous successes [1] E-Commerce Strategy - In 2025, e-commerce accounted for over 50% of SenesTech's revenue, with approximately half of that managed directly by the company [1] - The transition to in-house management of Amazon sales is expected to provide greater control over product presentation and consumer communications [1] - Direct management will enable the company to retain a larger portion of e-commerce revenue and enhance direct-to-consumer capabilities [1] Operational Enhancements - SenesTech has expanded its internal e-commerce resources, including leadership support and operational expertise, to facilitate this transition [1] - The implementation of direct management is set for Q1, with financial benefits expected to be more pronounced in Q2 [1] Product Overview - Evolve is a non-lethal rodent control solution that targets rodent overpopulation by reducing fertility, offering a sustainable alternative to traditional poisons [1] - The product is designed to integrate into pest management programs, enhancing their effectiveness while minimizing reliance on harmful chemicals [1]